Empagliflozin for People Receiving Hemodialysis
Safety and Efficacy of Empagliflozin Main intenance HD (SEED)
This project explores if a medication called empagliflozin can improve health outcomes for individuals receiving regular hemodialysis for end-stage kidney disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11121741 on NIH RePORTER |
What this research studies
Patients with end-stage kidney disease who are on hemodialysis often experience serious heart problems and frequent hospital stays, and there are few proven therapies to reduce these risks. A type of medication called SGLT2 inhibitors, including empagliflozin, has shown great promise in protecting the kidneys and heart in people with earlier stages of chronic kidney disease. This work aims to determine if empagliflozin can provide similar protective benefits and improve the overall health of people already undergoing maintenance hemodialysis. We want to understand if this medication is both safe and effective for this specific patient group.
Who could benefit from this research
Good fit: Ideal candidates are adults aged 21 and older who are currently receiving maintenance hemodialysis for end-stage kidney disease.
Not a fit: Patients who are not on hemodialysis or who do not have end-stage kidney disease may not directly benefit from this specific medication in this context.
Why it matters
Potential benefit: If successful, this medication could significantly reduce heart-related complications and hospitalizations for people on maintenance hemodialysis.
How similar studies have performed: SGLT2 inhibitors have shown significant benefits in patients with chronic kidney disease, but their effectiveness specifically in patients on maintenance hemodialysis is still being explored.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Charytan, David M — New York University School of Medicine
- Study coordinator: Charytan, David M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.